Corey Smith

Dr. Corey Smith


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Immunity
Verified
Journal Article
Closed access
KLKatie E. Lineburg
Katie E. Lineburg
EGEmma J. Grant
Emma J. Grant
SSSrividhya Swaminathan
Srividhya Swaminathan
DCDemetra S.M. Chatzileontiadou
Demetra S.M. Chatzileontiadou
CSChristopher Szeto
Christopher Szeto
Stephanie GrasStephanie Gras
Stephanie Gras

15 November 2018 in JCI Insight
Verified
Journal Article
Open access
PDF file
MPMichael P. Pender
Michael P. Pender
PCPeter A. Csurhes
Peter A. Csurhes
CSCorey Smith
Corey Smith
NDNanette L. Douglas
Nanette L. Douglas
MNMichelle A. Neller
Michelle A. Neller
RKRajiv Khanna
Rajiv Khanna
BACKGROUND. Increasing evidence indicates a role for EBV in the pathogenesis of multiple sclerosis (MS). EBV-infected autoreactive B cells might accumulate in the CNS because of defective cytotoxic CD8 + T cell immunity. We sought to determine the feasibility and safety of treating progressive MS patients with autologous EBV-specific T cell therapy. METHODS. An open-label phase I trial was designed to treat 5 patients with secondary progressive MS and 5 patients with primary progressive MS with 4 escalating doses of in vitro–expanded autologous EBV-specific T cells targeting EBV nuclear antigen 1, latent membrane protein 1 (LMP1), and LMP2A. Following adoptive immunotherapy, we monitored the patients for safety and clinical responses. RESULTS. Of the 13 recruited participants, 10 received the full course of T cell therapy. There were no serious adverse events. Seven patients showed improvement, with 6 experiencing both symptomatic and objective neurological improvement, together with a reduction in fatigue, improved quality of life, and, in 3 patients, reduced intrathecal IgG production. All 6 patients receiving T cells with strong EBV reactivity showed clinical improvement, whereas only 1 of the 4 patients receiving T cells with weak EBV reactivity showed improvement ( P = 0.033, Fisher’s exact test). CONCLUSION. EBV-specific adoptive T cell therapy was well tolerated. Clinical improvement following treatment was associated with the potency of EBV-specific reactivity of the administered T cells. Further clinical trials are warranted to determine the efficacy of EBV-specific T cell therapy in MS. TRIAL REGISTRATION. Australian New Zealand Clinical Trials Registry, ACTRN12615000422527. FUNDING. MS Queensland, MS Research Australia, Perpetual Trustee Company Ltd., and donations from private individuals who wish to remain anonymous.

19 May 2016 in JCI Insight
Verified
Journal Article
Open access
PDF file
KTKirsteen M. Tullett
Kirsteen M. Tullett
IRIngrid M. Leal Rojas
Ingrid M. Leal Rojas
YMYoshihito Minoda
Yoshihito Minoda
PTPeck S. Tan
Peck S. Tan
JZJian-Guo Zhang
Jian-Guo Zhang
KRKristen Radford
Kristen Radford
DC-based vaccines that initiate T cell responses are well tolerated and have demonstrated efficacy for tumor immunotherapy, with the potential to be combined with other therapies. Targeting vaccine antigens (Ag) directly to the DCs in vivo is more effective than cell-based therapies in mouse models and is therefore a promising strategy to translate to humans. The human CD141 + DCs are considered the most clinically relevant for initiating CD8 + T cell responses critical for killing tumors or infected cells, and they specifically express the C-type lectin-like receptor CLEC9A that facilitates presentation of Ag by these DCs. We have therefore developed a human chimeric Ab that specifically targets CLEC9A on CD141 + DCs in vitro and in vivo. These human chimeric Abs are highly effective at delivering Ag to DCs for recognition by both CD4 + and CD8 + T cells. Given the importance of these cellular responses for antitumor or antiviral immunity, and the superior specificity of anti-CLEC9A Abs for this DC subset, this approach warrants further development for vaccines.

2 November 2020 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
CSCorey Smith
Corey Smith
KLKatie E. Lineburg
Katie E. Lineburg
PMPaulo Martins
Paulo Martins
GAGeorge R. Ambalathingal
George R. Ambalathingal
MNMichelle A. Neller
Michelle A. Neller
RKRajiv Khanna
Rajiv Khanna
BACKGROUND. The recent failure of checkpoint-blockade therapies for glioblastoma multiforme (GBM) in late-phase clinical trials has directed interest toward adoptive cellular therapies (ACTs). In this open-label, first-in-human trial, we have assessed the safety and therapeutic potential of cytomegalovirus-specific (CMV-specific) ACT in an adjuvant setting for patients with primary GBM, with an ultimate goal to prevent or delay recurrence and prolong overall survival. METHODS. Twenty-eight patients with primary GBM were recruited to this prospective study, 25 of whom were treated with in vitro–expanded autologous CMV-specific T cells. Participants were monitored for safety, progression-free survival, overall survival (OS), and immune reconstitution. RESULTS. No participants showed evidence of ACT-related toxicities. Of 25 evaluable participants, 10 were alive at the completion of follow-up, while 5 were disease free. Reconstitution of CMV-specific T cell immunity was evident and CMV-specific ACT may trigger a bystander effect leading to additional T cell responses to nonviral tumor-associated antigens through epitope spreading. Long-term follow-up of participants treated before recurrence showed significantly improved OS when compared with those who progressed before ACT (median 23 months, range 7–65 vs. median 14 months, range 5–19; P = 0.018). Gene expression analysis of the ACT products indicated that a favorable T cell gene signature was associated with improved long-term survival. CONCLUSION. Data presented in this study demonstrate that CMV-specific ACT can be safely used as an adjuvant therapy for primary GBM and, if offered before recurrence, this therapy may improve OS of GBM patients. TRIAL REGISTRATION. anzctr.org.au: ACTRN12615000656538. FUNDING. Philanthropic funding and the National Health and Medical Research Council (Australia).

16 January 2015 in Clinical & Translational Immunology
Verified
Journal Article
Open access
CSCorey Smith
Corey Smith
GØGrethe Økern
Grethe Økern
SRSweera Rehan
Sweera Rehan
LBLeone Beagley
Leone Beagley
SLSau K Lee
Sau K Lee
RKRajiv Khanna
Rajiv Khanna
The manufacture of clinical grade cellular products for adoptive immunotherapy requires ex vivo culture and expansion of human T cells. One of the key components in manufacturing of T cell therapies is human serum (HS) or fetal bovine serum (FBS), which can potentially expose immunotherapy recipient to adventitious infectious pathogens and are thus considered as non‐cGMP compliant for adoptive therapy. Here we describe a novel xeno‐free serum replacement (SR) with defined components that can be reproducibly used for the production of clinical grade T‐cell therapies in combination with several different cell culture media. Dynabeads CD3/CD28 Cell Therapy System (CTS)‐activated or antigen‐specific T cells expanded using the xeno‐free SR, CTS Immune Cell SR, showed comparable growth kinetics observed with cell culture media supplemented with HS or FBS. Importantly the xeno‐free SR supplemented medium supported the optimal expansion of T cells specific for subdominant tumour‐associated antigens and promoted expansion of T cells with central memory T‐cell phenotype, which is favourable for in vivo survival and persistence following adoptive transfer. Furthermore, T cells expanded using xeno‐free SR medium were highly amenable to lentivirus‐mediated gene transduction for potential application for gene‐modified T cells. Taken together, the CTS Immune Cell SR provides a novel platform strategy for the manufacture of clinical grade adoptive cellular therapies.

15 June 2009 in Journal of Virology
Verified
Journal Article
Open access
CSCorey Smith
Corey Smith
LBLeone Beagley
Leone Beagley
RKRajiv Khanna
Rajiv Khanna
Latent membrane antigen 1 and -2 (LMP-1/2)-specific CD8 + T cells from newly diagnosed and relapsed Hodgkin's lymphoma (HL) patients display a selective functional impairment. In contrast, CD8 + T cells specific for Epstein-Barr virus (EBV) nuclear proteins and lytic antigens retain normal T-cell function. Reversion to a dysfunctional phenotype of LMP-1/2-specific T cells is coincident with the regression of HL. To delineate the potential basis for this differential susceptibility for the loss of function, we have carried out a comprehensive functional analysis of EBV-specific T cells using ex vivo multiparametric flow cytometry in combination with assessment of antigen-driven proliferative potential. This analysis revealed that LMP-1/2-specific T cells from healthy virus carriers display a deficient polyfunctional profile compared to that of T cells specific for epitopes derived from EBV nuclear proteins and lytic antigens. Furthermore, LMP-specific T-cells are highly susceptible to galectin-1-mediated immunosuppression and are less likely to degranulate following exposure to cognate peptide epitopes and poorly recognized endogenously processed epitopes from virus-infected B cells. More importantly, ex vivo stimulation of these T cells with an adenoviral vector encoding multiple minimal CD8 + T-cell epitopes as a polyepitope, in combination with a γC cytokine, interleukin-2, restored polyfunctionality and shielded these cells from the inhibitory effects of galectin-1.